Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial): Design and methods

Nathan K LeBrasseur, Newsha Lajevardi, Renee Miciek, Norman Mazer, Thomas W. Storer, Shalender Bhasin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The TOM study is the first, single-site, placebo-controlled, randomized clinical trial designed to comprehensively determine the effects of testosterone administration on muscle strength and physical function in older men with mobility limitations. A total of 252 community dwelling individuals aged 65 and older with low testosterone levels and self-reported limitations in mobility and short physical performance battery (SPPB) scores between 4 and 9 will be randomized to receive either placebo or testosterone therapy for 6 months. The primary objective is to determine whether testosterone therapy improves maximal voluntary muscle strength as quantified by the one repetition maximum. Secondary outcomes will include measures of physical function (walking, stair climbing and a lifting and lowering task), habitual physical activity and self-reported disability. The effects of testosterone on affect, fatigue and sense of well being will also be assessed. Unique aspects of the TOM Trial include selection of men with self-reported as well as objectively demonstrable functional limitations, community-based screening and recruitment, adjustment of testosterone dose to ensure serum testosterone levels in the target range while maintaining blinding, and inclusion of a range of self-reported and performance-based physical function measures as outcomes. Clinicaltrials.gov identifier: NCT00240981.

Original languageEnglish (US)
Pages (from-to)133-140
Number of pages8
JournalContemporary Clinical Trials
Volume30
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Mobility Limitation
Testosterone
Muscles
Muscle Strength
Therapeutics
Placebos
Independent Living
Walking
Fatigue
Skeletal Muscle
Randomized Controlled Trials
Outcome Assessment (Health Care)
Exercise
Serum

Keywords

  • Aging
  • Anabolic therapies
  • Mobility limitations
  • Physical function
  • Sarcopenia
  • Strength
  • Testosterone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial) : Design and methods. / LeBrasseur, Nathan K; Lajevardi, Newsha; Miciek, Renee; Mazer, Norman; Storer, Thomas W.; Bhasin, Shalender.

In: Contemporary Clinical Trials, Vol. 30, No. 2, 03.2009, p. 133-140.

Research output: Contribution to journalArticle

LeBrasseur, Nathan K ; Lajevardi, Newsha ; Miciek, Renee ; Mazer, Norman ; Storer, Thomas W. ; Bhasin, Shalender. / Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial) : Design and methods. In: Contemporary Clinical Trials. 2009 ; Vol. 30, No. 2. pp. 133-140.
@article{606a93eebef64c7b84fe67a3233fed7c,
title = "Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial): Design and methods",
abstract = "The TOM study is the first, single-site, placebo-controlled, randomized clinical trial designed to comprehensively determine the effects of testosterone administration on muscle strength and physical function in older men with mobility limitations. A total of 252 community dwelling individuals aged 65 and older with low testosterone levels and self-reported limitations in mobility and short physical performance battery (SPPB) scores between 4 and 9 will be randomized to receive either placebo or testosterone therapy for 6 months. The primary objective is to determine whether testosterone therapy improves maximal voluntary muscle strength as quantified by the one repetition maximum. Secondary outcomes will include measures of physical function (walking, stair climbing and a lifting and lowering task), habitual physical activity and self-reported disability. The effects of testosterone on affect, fatigue and sense of well being will also be assessed. Unique aspects of the TOM Trial include selection of men with self-reported as well as objectively demonstrable functional limitations, community-based screening and recruitment, adjustment of testosterone dose to ensure serum testosterone levels in the target range while maintaining blinding, and inclusion of a range of self-reported and performance-based physical function measures as outcomes. Clinicaltrials.gov identifier: NCT00240981.",
keywords = "Aging, Anabolic therapies, Mobility limitations, Physical function, Sarcopenia, Strength, Testosterone",
author = "LeBrasseur, {Nathan K} and Newsha Lajevardi and Renee Miciek and Norman Mazer and Storer, {Thomas W.} and Shalender Bhasin",
year = "2009",
month = "3",
doi = "10.1016/j.cct.2008.10.005",
language = "English (US)",
volume = "30",
pages = "133--140",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial)

T2 - Design and methods

AU - LeBrasseur, Nathan K

AU - Lajevardi, Newsha

AU - Miciek, Renee

AU - Mazer, Norman

AU - Storer, Thomas W.

AU - Bhasin, Shalender

PY - 2009/3

Y1 - 2009/3

N2 - The TOM study is the first, single-site, placebo-controlled, randomized clinical trial designed to comprehensively determine the effects of testosterone administration on muscle strength and physical function in older men with mobility limitations. A total of 252 community dwelling individuals aged 65 and older with low testosterone levels and self-reported limitations in mobility and short physical performance battery (SPPB) scores between 4 and 9 will be randomized to receive either placebo or testosterone therapy for 6 months. The primary objective is to determine whether testosterone therapy improves maximal voluntary muscle strength as quantified by the one repetition maximum. Secondary outcomes will include measures of physical function (walking, stair climbing and a lifting and lowering task), habitual physical activity and self-reported disability. The effects of testosterone on affect, fatigue and sense of well being will also be assessed. Unique aspects of the TOM Trial include selection of men with self-reported as well as objectively demonstrable functional limitations, community-based screening and recruitment, adjustment of testosterone dose to ensure serum testosterone levels in the target range while maintaining blinding, and inclusion of a range of self-reported and performance-based physical function measures as outcomes. Clinicaltrials.gov identifier: NCT00240981.

AB - The TOM study is the first, single-site, placebo-controlled, randomized clinical trial designed to comprehensively determine the effects of testosterone administration on muscle strength and physical function in older men with mobility limitations. A total of 252 community dwelling individuals aged 65 and older with low testosterone levels and self-reported limitations in mobility and short physical performance battery (SPPB) scores between 4 and 9 will be randomized to receive either placebo or testosterone therapy for 6 months. The primary objective is to determine whether testosterone therapy improves maximal voluntary muscle strength as quantified by the one repetition maximum. Secondary outcomes will include measures of physical function (walking, stair climbing and a lifting and lowering task), habitual physical activity and self-reported disability. The effects of testosterone on affect, fatigue and sense of well being will also be assessed. Unique aspects of the TOM Trial include selection of men with self-reported as well as objectively demonstrable functional limitations, community-based screening and recruitment, adjustment of testosterone dose to ensure serum testosterone levels in the target range while maintaining blinding, and inclusion of a range of self-reported and performance-based physical function measures as outcomes. Clinicaltrials.gov identifier: NCT00240981.

KW - Aging

KW - Anabolic therapies

KW - Mobility limitations

KW - Physical function

KW - Sarcopenia

KW - Strength

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=60249103687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249103687&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2008.10.005

DO - 10.1016/j.cct.2008.10.005

M3 - Article

C2 - 18996225

AN - SCOPUS:60249103687

VL - 30

SP - 133

EP - 140

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 2

ER -